It rebounded significantly after 5 days. It has been announced that a patent for the application of peptide drugs created from the regenerative induction pharmaceutical development candidate Ledacemtide (HMGB1) derived to Shionogi <4507> has been registered in japan. The patent secures the possibility of developing therapeutic drugs for inflammatory bowel diseases (ulcerative colitis, Crohn's disease). Ledacemtide has shown effects such as suppressing weight loss in animal models of inflammatory bowel diseases and suppressing inflammation.
ステムリム---大幅に5日ぶり反発、再生誘導医薬レダセムチド創製ペプチドが日本で特許登録
Stem inc - significantly rebounded after 5 days, regenerative induction medicine Ledacemtide created peptide patented in japan.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated